174 related articles for article (PubMed ID: 16987706)
1. GLP-1 and type 2 diabetes: physiology and new clinical advances.
Combettes MM
Curr Opin Pharmacol; 2006 Dec; 6(6):598-605. PubMed ID: 16987706
[TBL] [Abstract][Full Text] [Related]
2. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes.
Kendall DM; Kim D; Maggs D
Diabetes Technol Ther; 2006 Jun; 8(3):385-96. PubMed ID: 16800760
[TBL] [Abstract][Full Text] [Related]
3. Clinical approaches to preserve beta-cell function in diabetes.
Wajchenberg BL
Adv Exp Med Biol; 2010; 654():515-35. PubMed ID: 20217513
[TBL] [Abstract][Full Text] [Related]
4. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
5. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
6. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
7. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
8. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
Triplitt C; Wright A; Chiquette E
Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
[TBL] [Abstract][Full Text] [Related]
9. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
10. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells.
Ma X; Guan Y; Hua X
J Diabetes; 2014 Sep; 6(5):394-402. PubMed ID: 24725840
[TBL] [Abstract][Full Text] [Related]
13. Molecular physiology of glucagon-like peptide-1 insulin secretagogue action in pancreatic β cells.
Leech CA; Dzhura I; Chepurny OG; Kang G; Schwede F; Genieser HG; Holz GG
Prog Biophys Mol Biol; 2011 Nov; 107(2):236-47. PubMed ID: 21782840
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets.
Tudurí E; López M; Diéguez C; Nadal A; Nogueiras R
Trends Endocrinol Metab; 2016 May; 27(5):304-318. PubMed ID: 27062006
[TBL] [Abstract][Full Text] [Related]
15. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
16. Incretin-based therapy and type 2 diabetes.
Hare KJ; Knop FK
Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
[TBL] [Abstract][Full Text] [Related]
17. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
Yabe D; Seino Y
Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
[TBL] [Abstract][Full Text] [Related]
18. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
19. [The incretin effect: a new therapeutic target in type 2 diabetes].
Féry F
Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
[TBL] [Abstract][Full Text] [Related]
20. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]